LAMP

Finseca's 2024 Hall of Fame Inductees Announced

Retrieved on: 
Tuesday, March 19, 2024
MassMutual, 38th AVN Awards, Fame Awards, Science, LAMP, Insurance, FBL Financial Group, Hall

"We are thrilled to announce this year's Hall of Fame class," said Bonnie Godsman, Finseca's President.

Key Points: 
  • "We are thrilled to announce this year's Hall of Fame class," said Bonnie Godsman, Finseca's President.
  • Finseca's Hall of Fame Award is regarded as the highest honor bestowed upon distinguished insurance and financial security leaders.
  • Nominees were evaluated by the Hall of Fame Selection Committee, which assessed each nominee's history and accomplishments in four categories:
    Advancing the art and science of agency/firm building.
  • For more information about the Finseca Hall of Fame Awards and this year's inductees, please visit finseca.org/communities/leadership-awardees.

Anthony T. Mazzei, Sr. Inducted into Finseca Hall of Fame

Retrieved on: 
Monday, March 18, 2024
38th AVN Awards, Fame Awards, Science, LAMP, Insurance, Retirement, General agent, Hall, Management

His induction into the Finseca Hall of Fame is a fitting tribute to his work, and we know his efforts to elevate the industry will only continue."

Key Points: 
  • His induction into the Finseca Hall of Fame is a fitting tribute to his work, and we know his efforts to elevate the industry will only continue."
  • Tony embodies what it means to be a General Agent and Finseca has made an outstanding choice in inducting him into its Hall of Fame."
  • His induction into the Finseca Hall of Fame is a fitting tribute to his work, and we know his efforts to elevate the industry will only continue.
  • For more information about the Finseca Hall of Fame Awards and this year's inductees, please visit finseca.org/communities/leadership-awardees.

Alveo Technologies Is Developing Groundbreaking Avian Influenza Molecular Test for Poultry in Partnership with x-OvO, Royal GD, and Pharmsure

Retrieved on: 
Tuesday, January 9, 2024
David Gal, Farmer, Health, Knowledge, Food security, Royal, Risk, Pandemic, WHO, Disease, Laboratory, Liver function tests, LAMP, Data collection, PCR, Infection, Group A, WOAH, Diagnosis, Bird, Vaccine

ALAMEDA, Calif., Jan. 9, 2024 /PRNewswire/ -- Alveo Technologies, Inc. (Alveo), a leader in molecular sensing and diagnostics with its proprietary be.well technology platform, today announced it is working with experts and leaders in the poultry industry to launch a rapid, accurate, in-the-field multiplex panel to test for all relevant strains of avian influenza, initially focusing on Group A, H5, H7, and H9. To help codevelop and distribute the tests, Alveo has partnered with industry leaders x-OvO, Royal GD, and Pharmsure International Ltd. The company expects to release their first product in the poultry diagnostic space, in EMEA in the first half of 2024.  

Key Points: 
  • To help codevelop and distribute the tests, Alveo has partnered with industry leaders x-OvO, Royal GD, and Pharmsure International Ltd.
  • The avian flu test will be Alveo's first product to launch into the agricultural sector since Alveo announced its open platform and partnering strategy last year.
  • In addition to avian flu, Alveo is partnering to develop test panels for many other pathogens impacting the agriculture industry.
  • "We've been working closely with Alveo in a deep collaboration to develop these highly valuable assays for Avian Influenza," said Wim Kieftenbeld, Director Business Development at Royal GD.

Laboratory Testing and PCR Technology Lead the India Infectious Disease Diagnostics Market, Transforming Disease Detection and Management - ResearchAndMarkets.com

Retrieved on: 
Wednesday, November 8, 2023
Health, Infectious Diseases, Pathogen, Laboratory, Research, Public health surveillance, RPA, Molecular biology, Infection, Parasitism, Biomarker, Contact tracing, Research and development, CRISPR, PCR, Disease, Sputum, Fungus, Virulence, LAMP, Whole genome sequencing, Artificial intelligence, Vaccination, Urine, NGS, Diagnosis, COVID-19, Medicine, WGS, Blood, Microscopy, Public, Gene expression, DNA, Vaccine, Pharmaceutical industry, Epidemiology

The India emerging infectious disease diagnostics market is set for substantial growth over the forecast period from 2023 to 2033.

Key Points: 
  • The India emerging infectious disease diagnostics market is set for substantial growth over the forecast period from 2023 to 2033.
  • The India emerging infectious disease diagnostics market is currently in an emerging phase.
  • The India emerging infectious disease diagnostics market plays a pivotal role in modern biotechnology, clinical diagnostics, and pathogen research.
  • The India emerging infectious disease diagnostics market is segmented into key categories:
    In FY2022, laboratory testing was the dominant application segment in the India emerging infectious disease diagnostics market.

Immunomic Therapeutics Reports Positive Results from Its Phase 1 Clinical Trial of ITI-3000 in Patients Diagnosed with Merkel Cell Carcinoma

Retrieved on: 
Monday, October 23, 2023
Oncology, Health, Other Science, Clinical Trials, Research, Science, Biotechnology, FDA, Standard of care, SOC, Angela Merkel, Food, Fast track (FDA), NEAD, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, MCC, LAMP, ITI, FIH, Clinical trial, Recurrence, Merkel cell polyomavirus, Safety, Plasmid, Therapy, Patient, Skin cancer, FTD, DNA, Merkel-cell carcinoma, Pharmaceutical industry

ITI-3000 was granted Fast Track Designation (FTD) by the U.S. Food and Drug Administration (FDA) in November 2022.

Key Points: 
  • ITI-3000 was granted Fast Track Designation (FTD) by the U.S. Food and Drug Administration (FDA) in November 2022.
  • As we are encouraged by the immunological responses in patients, we look forward to continuing the development of ITI-3000.
  • The phase 1 clinical trial was a six-patient, single center, open label, first-in-human (FIH) study, investigating the safety, tolerability and immunogenicity of ITI-3000 in patients with polyomavirus-positive Merkel cell carcinoma (MCC).
  • Additional information regarding the phase 1 trial may be found at clinicaltrials.gov , using identifier: NCT05422781.

Anbio Biotechnology Made a Successful First Presence at AACC Middle East 2023

Retrieved on: 
Monday, October 16, 2023
IVD, Polymerase chain reaction, LAMP, FIA, Platinum, POCT, CLIA, Ambulance, LFA, Chemiluminescent immunoassay, Lateral flow test, Biotechnology, Medical device

FRANKFURT, Germany, Oct. 16, 2023 /PRNewswire/ --  Anbio Biotechnology ("Anbio"), a leading provider of innovative diagnostic solutions, successfully showcased its debut at AACC Middle East 2023 held in Dubai from October 7-8, 2023.

Key Points: 
  • FRANKFURT, Germany, Oct. 16, 2023 /PRNewswire/ --  Anbio Biotechnology ("Anbio"), a leading provider of innovative diagnostic solutions, successfully showcased its debut at AACC Middle East 2023 held in Dubai from October 7-8, 2023.
  • Anbio is the platinum sponsor of AACC Middle East this year.
  • This successfully presence has further showcased Anbio's commitment to advanced, affordable, reliable product solutions and made huge progress toward greater recognition in Middle East area.
  • "Anbio's official launch in the Middle East market at AACC Middle East 2023 is a milestone moment for the company, " said Michael Lau.

Anbio Biotechnology Made a Successful Presence at Medic East Africa 2023

Retrieved on: 
Monday, September 18, 2023
DNA, Exhibition, FIA, Infection, DSM-IV codes, Inflammation, RNA, LAMP, Hormone, LFA, Loop-mediated isothermal amplification, Patient, Laboratory, Lateral flow test, OTC, IVD, POC, Vaccine

FRANKFURT, Germany, Sept. 18, 2023 /PRNewswire/ -- Anbio, a global leading provider of innovative diagnostic solutions, made a successful exhibition at Medic East Africa 2023 from September 13th to 15th.

Key Points: 
  • FRANKFURT, Germany, Sept. 18, 2023 /PRNewswire/ -- Anbio, a global leading provider of innovative diagnostic solutions, made a successful exhibition at Medic East Africa 2023 from September 13th to 15th.
  • With over 60 available LFA assays, Anbio will continue to invest in R&D and provide customers with more trusted products.
  • ­­ Michael Lau, CEO of Anbio commented: "I wanted to thank everyone who visited our booth at Medic East Africa 2023.
  • We had a successful exhibition, and we look forward to providing our IVD products for the betterment of the diagnostic and healthcare system in Africa and globally."

Anbio Biotechnology Highlights the Future of Diagnostic Solutions at AACC 2023

Retrieved on: 
Tuesday, August 1, 2023
Diagnosis, AACC, Colloidal gold, FIA, Lecture, Enzyme, Infection, LAMP, Hormone, POCT, CLIA, Patient, Lateral flow test, IVD, Medical device

FRANKFURT, Germany, Aug. 1, 2023 /PRNewswire/ -- Anbio, a leading provider of innovative diagnostic solutions, made a successful market presence at the 2023 American Association for Clinical Chemistry (AACC) Annual Scientific Meeting & Clinical Lab Expo held in Anaheim, CA from July 25-27.

Key Points: 
  • FRANKFURT, Germany, Aug. 1, 2023 /PRNewswire/ -- Anbio, a leading provider of innovative diagnostic solutions, made a successful market presence at the 2023 American Association for Clinical Chemistry (AACC) Annual Scientific Meeting & Clinical Lab Expo held in Anaheim, CA from July 25-27.
  • During the tradeshow, Anbio showcased a range of solutions, including CLIA, FIA, LAMP, RT-PCR and Lateral Flow while also demonstrating the operation process of analyzers.
  • The lecture attracted hundreds of attendees, where Michael shared insights into the company's background, comprehensive diagnostic product solutions, and emphasized Anbio's manufacturing capabilities.
  • "AACC 2023 marks the official launch of Anbio's products in the North American market," Michael stated during the lecture.

USDA and Cooperators Boost Reduction and Re-utilization of Food Loss and Waste in Asia

Retrieved on: 
Wednesday, July 26, 2023
CFP, Community Food Projects, Buzby, Livestock, LAMP, Associate, Natural Resources, Plasma, Nutrient, Collection, REAP, Flemish people, NARA, Tissue, Poverty, Recycling, University, NSF, Research, Federal, ASMI, EPA, Salmon, Food, Conservation, and Energy Act of 2008, Quality control, Growth, FDA, Sustainable development, Safety, Food, Poultry, Compositing, Aquaculture, United Nations General Assembly, Multimedia, Foreign Agricultural Service, Carbon, Government, Royal Canin, Wisconsin Department of Agriculture, Trade and Consumer Protection, Zhejiang University, CFWR, Farm Storage Facility Loan Program, Water, Sustainable Development Goals, Methane, Forum, United Nations, FLW, Temporary Emergency Food Assistance Program, Developed country, USDA, Pet, APC, Agriculture, Renewable energy

The aim of this forum was to boost reduction of escalating FLW across the globe and potential re-utilization through innovative technologies.

Key Points: 
  • The aim of this forum was to boost reduction of escalating FLW across the globe and potential re-utilization through innovative technologies.
  • USDA's Agricultural Trade Office (ATO) in Guangzhou launched this forum and hopes to hold similar discussions in the future.
  • The last two presentations focused on food waste, where an average of 17% waste in total food supply chain was estimated to occur post-retail.
  • Recycling of nutrients from food waste from selected sources (i.e., food supermarkets) via industrialized husbandry of black soldier fly appears a more viable solution to food waste re-utilization  than general composting and direct animal feeding.

Fapon to Showcase Innovative Diagnostic and Biopharma Solutions at 2023 AACC Expo

Retrieved on: 
Monday, July 24, 2023
Wuhan Institute of Biological Products, Monoclonal antibody, AACC, CD19, Exhibition, Small RNA, CMC, Immunoassay, RNA, LAMP, CLIA, RSV, Laboratory, Drug discovery, CFO, IVD, Diagnosis, Ortho Clinical Diagnostics, CIO, PCR, Medical device, Vaccine

ANAHEIM, Calif., July 24, 2023 /PRNewswire/ -- Fapon, a leading life science company, will showcase its latest innovations in in-vitro diagnostic and biopharma solutions at the 2023 American Association of Clinical Chemistry (AACC) Scientific Meeting and Clinical Lab Expo from July 25 to 27.

Key Points: 
  • ANAHEIM, Calif., July 24, 2023 /PRNewswire/ -- Fapon, a leading life science company, will showcase its latest innovations in in-vitro diagnostic and biopharma solutions at the 2023 American Association of Clinical Chemistry (AACC) Scientific Meeting and Clinical Lab Expo from July 25 to 27.
  • Rooted in IVD raw materials for 22 years, Fapon will showcase its comprehensive core IVD raw materials solutions for immunoassay and PCR & LAMP.
  • Fapon Biopharma, a subsidiary of Fapon, has developed a fully-integrated platform that includes programs from discovery to clinical research stages for novel biological products.
  • "We are thrilled to be showcasing our latest solutions and offerings at the 2023 AACC Expo," said Jielun ZHU, CFO & CIO of Fapon.